Aroa Biosurgery (ASX:ARX) EBITDA Margin % : -7.59% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Aroa Biosurgery EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Aroa Biosurgery's EBITDA for the six months ended in Mar. 2024 was A$-2.61 Mil. Aroa Biosurgery's Revenue for the six months ended in Mar. 2024 was A$34.38 Mil. Therefore, Aroa Biosurgery's EBITDA margin for the quarter that ended in Mar. 2024 was -7.59%.

Aroa Biosurgery EBITDA Margin % Historical Data

The historical data trend for Aroa Biosurgery's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aroa Biosurgery EBITDA Margin % Chart

Aroa Biosurgery Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

EBITDA Margin %

-65.00

-11.04

5.46

-6.90

Aroa Biosurgery Semi-Annual Data
	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
EBITDA Margin %	Get a 7-Day Free Trial			-7.85	17.20	-3.31	-6.08	-7.59

Competitive Comparison of Aroa Biosurgery's EBITDA Margin %

For the Medical Devices subindustry, Aroa Biosurgery's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aroa Biosurgery's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Aroa Biosurgery's EBITDA Margin % falls into.

Aroa Biosurgery EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Aroa Biosurgery's EBITDA Margin % for the fiscal year that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (A: Mar. 2024 )	/	Revenue (A: Mar. 2024 )
	=	-4.37	/	63.357
	=	-6.90 %

Aroa Biosurgery's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-2.61	/	34.382
	=	-7.59 %

Aroa Biosurgery (ASX:ARX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Aroa Biosurgery EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Aroa Biosurgery's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aroa Biosurgery (ASX:ARX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aroa Biosurgery Ltd (ASX:ARX) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022

Website

https://www.aroabio.com

Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.

Aroa Biosurgery (ASX:ARX) Headlines

No Headlines